Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea
NCT: NCT04937309 · RECRUITING
Brief Summary
Despite pharmaceutical innovations, chemotherapy induced nausea is frequent and largely participating to alter our patients quality of life. Non invasive vagal stimulation is approved in other health issues, for example in headache or gastroparesis, with a reported benefit on nausea. This study aims to analyse if a non invasive vagal stimulation could better prevent chemotherapy induced nausea, in addition to standard treatment, in breast cancer patients treated with cyclophosphamide and anthracycline.
Frequently Asked Questions
What is Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea?
Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea is a clinical trial registered under NCT04937309. Current status: RECRUITING.
What is the status of NCT04937309?
The current status of NCT04937309 (Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea) is: RECRUITING.
When did Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea start?
Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea started on 2022-06-23.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.